Sunderland GT, Belch JJ, Sturrock RD, et al. A double-blind randomised placebo controlled trial of hexopal in primary Raynaud's disease.
Clin Rheumatol. 1988;7:46 - 49.
DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
Am J Med. 1989;86:158 - 164.
Ringer TV, Hughes GS, Spillers CR, et al. Fish oil blunts the pain response to cold pressor testing in normal males [abstract].
J Am Coll Nutr. 1989;8:435.
Belch JJ, Shaw B, O'Dowd A, et al. Evening primrose oil (Efamol) as a treatment for cold-induced vasospasm (Raynaud's phenomenon).
Prog Lipid Res.
1986;25:335 - 340.
Belch JJ, Shaw B, O'Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double-blind study.
Thromb Haemost. 1985;54:490 - 494.
Jung F, Mrowietz C, Kiesewetter H, et al. Effect of
on fluidity of blood and peripheral microcirculation in volunteers.
Arzneimittelforschung. 1990;40:589 - 593.
Khan F, Litchfield SJ, McLaren M, et al. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon.
Arthritis Rheum. 1997;40:352 - 357.
Muir AH, Robb R, McLaren M, et al. The use of ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial.
Vasc Med. 2002;7:265 - 267.
Mavrikakis ME, Lekakis JP, Papamichael CM, et al. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
Int J Vitam Nutr Res. 2003;73:3 - 7.
Raynaud's Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud's phenomenon. Results from a randomized clinical trial with 1-year follow-up.
Arch Intern Med. 2000;160:1101 - 1108.
Freedman RR, Ianni P, Wenig P. Behavioral treatment of Raynaud's phenomenon in scleroderma.
J Behav Med. 1984;7:343 - 353.